Superluminal Medicines raises $60 million Series B, Pulse2.com reports
Pulse2.com says the funding is intended to advance Superluminal’s lead obesity program into clinical development and expand its AI-enabled drug discovery platform.
Posts from X
P2 
Pulse 2.0@pulse2newsSuperluminal Medicines Raises $60 Million Series B Led By BVF Partners: Superluminal Medicines has raised an oversubscribed $60 million Series B financing led by BVF Partners to advance its lead obesity program into clinical development and expand its… https://dlvr.it/TVLJkr
- likes: 0
- replies: 0
- bookmarks: 0
- reposts: 0